Dermata Therapeutics, Inc. (DRMAW) — SEC Filings
Dermata Therapeutics, Inc. (DRMAW) — 40 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 28 8-K, 6 10-Q, 2 10-K.
View Dermata Therapeutics, Inc. on SEC EDGAR
Overview
Dermata Therapeutics, Inc. (DRMAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Dermata Therapeutics, Inc. announced on December 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 6 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Dermata Therapeutics, Inc. is neutral.
Filing Type Overview
Dermata Therapeutics, Inc. (DRMAW) has filed 28 8-K, 6 10-Q, 1 DEFA14A, 2 10-K, 1 SC 13G/A, 1 DEF 14A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of DRMAW's 36 recent filings, 7 were flagged as high-risk, 21 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$1,691,989 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $4,664,127 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Michael A. Smith
- Dr. David M. Lee
Industry Context
Dermata Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing treatments for dermatological conditions. This industry is characterized by long development cycles, significant R&D investment, and high failure rates. Success often hinges on securing substantial funding, navigating complex regulatory pathways, and achieving clinical efficacy.
Top Tags
filing (7) · material-agreement (4) · equity-sale (4) · delisting (4) · 10-Q (4) · 8-K (4) · 8-k (3) · corporate-action (3) · listing-standards (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-40739 | Identifies Dermata Therapeutics' filing with the SEC. |
| Net Loss (Q3 2025) | $1.7M | Reduced from $3.2M in Q3 2024, indicating improved operational efficiency or reduced spending. |
| Net Loss (9M 2025) | $5.7M | Reduced from $9.1M in 9M 2024, showing a positive trend in loss reduction. |
| Cash & Cash Equivalents | $4.7M | Increased from $3.2M at Dec 31, 2024, providing a short-term liquidity boost. |
| Financing Proceeds | $7.98M | Generated from equity and warrant issuance, crucial for funding operations. |
| R&D Expenses (9M 2025) | $2.4M | Significantly down from $6.0M in 9M 2024, impacting future product development pace. |
| Accumulated Deficit | $71.4M | Highlights the company's long-standing unprofitability and need for substantial future revenue. |
| Reverse Stock Split Ratio | 1-for-10 | Effected on August 1, 2025, to potentially boost share price and maintain Nasdaq listing. |
| Cash Runway | Q2 2026 | Expected period cash will fund operations, indicating an urgent need for additional capital. |
| Cash and cash equivalents | $6.48M | Increased from $3.16M at Dec 31, 2024, but still limited for operations. |
| Accumulated deficit | $69.68M | Indicates significant historical losses and going concern risk. |
| Net loss for H1 2025 | $4.00M | Improved from $5.96M in H1 2024, but still a substantial loss. |
| Research and development expenses for H1 2025 | $1.90M | Decreased significantly from $3.61M in H1 2024. |
| Net cash used in operating activities for H1 2025 | $4.62M | Slightly less than $4.83M in H1 2024, but still a high burn rate. |
| Proceeds from issuance of Common Stock and warrants | $7.99M | Primary source of cash, indicating reliance on dilutive financing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Dermata Therapeutics, Inc. (DRMAW)?
Dermata Therapeutics, Inc. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 28 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DRMAW filings?
Across 40 filings, the sentiment breakdown is: 6 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Dermata Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Dermata Therapeutics, Inc. (DRMAW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Dermata Therapeutics, Inc.?
Key financial highlights from Dermata Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DRMAW?
The investment thesis for DRMAW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Dermata Therapeutics, Inc.?
Key executives identified across Dermata Therapeutics, Inc.'s filings include Dr. Michael A. Smith, Dr. David M. Lee.
What are the main risk factors for Dermata Therapeutics, Inc. stock?
Of DRMAW's 36 assessed filings, 7 were flagged high-risk, 21 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Dermata Therapeutics, Inc.?
Forward guidance and predictions for Dermata Therapeutics, Inc. are extracted from SEC filings as they are enriched.